CONSOLIDATED STATEMENTS OF CASH FLOWS UNAUDITED (USD $) In Thousands, unless otherwise specified	9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012
Cash flows from operating activities:
Net income (loss)	$ 40,264	$ 135,856
Adjustments to reconcile net income to net cash flows from operating activities:
Depreciation expense	43,748	38,256
Amortization expense	61,073	63,377
Gains (Losses) on Extinguishment of Debt	(55,652)	(47,558)
Gain (Loss) on Sale of Business	36,062	0
Changes in assets and liabilities, net of effects from acquisition and divestiture of businesses:
Accounts receivable and unbilled receivables, net of provision for doubtful accounts	70,628	31,433
Inventories	(36,988)	82,786
Other current and noncurrent assets	(9,431)	65,341
Accounts payable	21,823	(95,172)
Accrued employee compensation	(17,941)	1,883
Current and noncurrent liabilities	189,775	45,585
Net cash flows from operating activities	454,665	416,903
Cash flows from investing activities:
Acquisition of businesses, net of cash received	(3,798)	(34,411)
Proceeds from Divestiture of Businesses, Net of Cash Divested	11,083	19,207
Payments to Acquire Marketable Securities	(620)	(25,000)
Capital expenditures	(74,127)	(71,433)
Other	1,061	1,348
Net cash flows used in investing activities	(66,401)	(110,289)
Cash flows from financing activities:
Payments on Term Loans	(15,938)	(19,375)
Proceeds from Issuance of Long-term Debt	0	425,000
Payments on long-term borrowings and obligations	(190,403)	(452,302)
Payments of Debt Issuance Costs	(4,851)	(7,164)
Option indexed to issuers equity cash paid	0	(48,126)
Increase (decrease) in cash overdraft balance	(11,490)	(1,540)
Payments for Omnicare common stock repurchases	91,259	110,919
Proceeds for stock awards and exercise of stock options, net of stock tendered in payment	17,934	5,710
Dividends paid	(43,011)	(30,765)
Other	2,228	13
Net Cash Provided by (Used in) Financing Activities	(336,790)	(239,468)
Net increase (decrease) in cash and cash equivalents	51,474	67,146
Cash and cash equivalents at beginning of period	454,213	580,262
Cash and cash equivalents at end of period	$ 505,687	$ 647,408